Neurodegenerative Disease Treatments

Posted by Tracy Hendershott on Jan 14, 2019 9:00:00 AM
Tracy Hendershott
Find me on:

Woman scientist touching DNA molecule image at media screen

While we have numerous symptomatic treatments today, there is still no cure for neurodegenerative diseases such as Parkinson’s and Alzheimer’s. There are more than 600 neurodegenerative diseases alone that affect the brain, spine, and peripheral nervous system. While diseases like Parkinson’s affect motor functions, Alzheimer’s is a progressive disease that destroys memory and other mental functions.

Currently, there are more than 5.5 million people in the United States alone who suffer from Alzheimer’s related symptoms, with an additional 6.3 million estimated worldwide suffering from Parkinson’s Disease.

This is why Eurofins Central Laboratory is pleased to participate in industry-leading, innovative analysis of both curative and symptomatic treatments for neurodegenerative diseases.  Much effort has been expended researching treatments focused on prions, neurons, astrocytes, and one of the most recent ones being AMP-activated protein kinase (AMPK).  AMPK is gaining recognition to be a potential therapeutic target in neuroinflammation-related diseases, by inducing an anti-inflammatory response via inhibition of activated microglia. Eurofins Discovery Services UK provided purified AMPK protein for the innovative team out of Korea, exploring this solution to the long-standing challenge of finding novel pathways toward a cure. 

At Eurofins BioPharma Services, we look forward to the evolution of these treatments out of the Discovery phase, into the Clinical phase, and supporting them with First in Man PH 1 protocols at Eurofins Optimed and then in PH II and III protocols at Eurofins Central Laboratory. Each one of these divisions is a critical component of the service offerings of Eurofins BioPharma Services

Eurofins BioPharma Services provides seamless, end-to-end solutions to help clients progress through the drug development cycle through a single, experienced provider. Our integrated solutions deliver the most comprehensive range of state-of-the-art analytical technologies, with an expansive geographic reach in order to support our clients’ specialized testing needs, stringent quality and safety requirements around the world. Whether your trial requires neurodegenerative specific biomarkers, like cerebrospinal fluid (CSF) Aβ, tau, phosphorylated tau and other neuronal proteins, PET tracers for Aβ, tau and glucose uptake or genomic based biomarkers, like APOE, PICALM, CLU, and BIN1; Eurofins BioPharma Services will collaborate with your research and development team, every step of the way.

For a closer examination of our end-to-end analytical capabilities in support of your neurodegenerative research, please reach out to begin the discussion.

 

 Read original article from Experimental Neurobiology

 

Tags: Central Laboratory, BioPharma, Alzheimer's Disease, Neurodegenerative, Parkinson's Disease